Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Isotope & Radiation Corp. ( (HK:1763) ) has shared an update.
China Isotope & Radiation Corporation announced the renewal of several key agreements, including supply, purchase, leasing, and financial services frameworks, for a term of three years starting from December 2025. These agreements are subject to approval by independent shareholders and are considered fair and reasonable by the company’s directors. The transactions are part of the company’s ordinary business operations and are expected to have implications for its market positioning and stakeholder interests, given their scale and the involvement of the controlling shareholder, CNNC.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation is a joint stock company incorporated in the People’s Republic of China. It operates in the isotope and radiation industry, focusing on the supply and purchase of isotopes and radiation-related products and services, including engineering construction and financial services. The company is a key player in its market, with significant involvement in connected transactions with its controlling shareholder, CNNC.
Average Trading Volume: 372,536
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.36B
For an in-depth examination of 1763 stock, go to TipRanks’ Overview page.